What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025BloodOpen Access

Outcomes of omidubicel-expanded umbilical cord blood transplantation in patients with severe aplastic anemia

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial found omidubicel transplantation achieves rapid engraftment and low graft versus host disease in severe aplastic anemia patients.

94% of patients achieved neutrophil recovery by day 8 after omidubicel transplantation, and 89% reached platelet recovery by day 24.
The conditioning regimen included total body irradiation and horse anti-thymocyte globulin to facilitate engraftment.
Patients demonstrated low rates of acute graft versus host disease, with a cumulative incidence of 17%.
Immune recovery was rapid, evidenced by increased CD4 counts and significant survival outcomes, despite adenovirus infections.

Farren et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial found omidubicel transplantation achieves rapid engraftment and low graft versus host disease in severe aplastic anemia patients.

94% of patients achieved neutrophil recovery by day 8 after omidubicel transplantation, and 89% reached platelet recovery by day 24.
The conditioning regimen included total body irradiation and horse anti-thymocyte globulin to facilitate engraftment.
Patients demonstrated low rates of acute graft versus host disease, with a cumulative incidence of 17%.
Immune recovery was rapid, evidenced by increased CD4 counts and significant survival outcomes, despite adenovirus infections.

Farren et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark